DNER and breast carcinoma: In this regard, it would be worth pre-clinically testing the efficacy of BET bromodomain inhibitors in diminishing the onset of disease in women at high-risk of developing breast cancer, such as those that are carriers of germline mutations in the tumor suppressor and DNA repair genes BRCA1 and BRCA2.